Relationships of Coagulation Factor XIII Activity with Cell-Type and Stage of Non-Small Cell Lung Cancer

Seung Heon Lee,1 In Bum Suh,2 Eun Joo Lee,2 Gyu Young Hur,4 Sung Yong Lee,4 Sang Yeub Lee,3 Chol Shin,1 Jae Jeong Shim,4 Kwang Ho In,3 Kyung Ho Kang,4 Se Hwa Yoo,3 and Je Hyeong Kim1

1Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan; 2Department of Clinical Pathology, College of Medicine, Kangwon National University, Chuncheon; 3Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul; 4Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

Received: January 3, 2013
Revised: February 21, 2013
Accepted: March 9, 2013
Corresponding author: Dr. Je Hyeong Kim, Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, 123 Jeokgeum-ro, Danwon-gu, Ansan 425-707, Korea. Tel: 82-31-412-5950, Fax: 82-31-413-5950 E-mail: chepraxis@korea.ac.kr

Purpose: Factor XIII (FXIII), a thrombin-activated plasma transglutaminase zymogen, is involved in cancer development and progression through a triggered coagulation pathway. The aim of this study was to examine whether FXIII activity levels differed in non-small cell lung cancer (NSCLC) patients according to histological types and TNM stage when compared with healthy subjects.

Materials and Methods: Twenty-eight NSCLC patients and 28 normal controls who had been individually age-, gender-, body mass index-, smoking status-, and smoking amount-matched were enrolled: 13 adenocarcinomas, 11 squamous cell carcinomas, and four undifferentiated NSCLCs; four stage I, two stage II, 12 stage III, and 10 stage IV NSCLCs. FXIII activity was measured using fluorescence-based protein arrays.

Results: The median FXIII activity level of the NSCLC group [24.2 Loewy U/mL, interquartile range (IQR) 14.9-40.4 Loewy U/mL] was significantly higher than that of the healthy group (17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) (p=0.01). There were no differences in FXIII activity between adenocarcinoma (median 18.6 Loewy U/mL) and squamous cell carcinoma (median 28.7 Loewy U/mL). NSCLC stage significantly influenced FXIII activity (p=0.02). The FXIII activity of patients with stage III NSCLC (median 27.3 Loewy U/mL, IQR 19.3-40.5 Loewy U/mL) was significantly higher than those of patients with stage I or II (median 14.0 Loewy U/mL, IQR 13.1-23.1 Loewy U/mL, p=0.04). FXIII activity was negatively correlated with aPTT in NSCLC patients (r=-0.38, p=0.04).

Conclusion: Patients with advanced-stage NSCLC exhibited higher coagulation FXIII activity than healthy controls and early-stage NSCLC patients.

Key Words: Factor XIII, histological type, neoplasm staging, non-small-cell lung carcinoma

© Copyright:
Yonsei University College of Medicine 2013
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Lung cancer is the primary cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about 75% of all lung cancer cases. Despite recent therapeutic advances in NSCLC, the overall 5-year survival is only around 15% for all stages. The main reason for treatment failure is delayed diagnosis, as the disease has often already achieved local advanced or metastatic phases by the time it is detected. Currently, there are no validated biomarkers for early lung cancer detection and tumor progression. Thus, the investigation of detective biomarkers has garnered great attention in lung cancer research.

Coagulation factors participate in inflammatory responses and tumorigenic conditions. About 50% of all cancer patients and 90% of patients with metastases show coagulation abnormalities of different levels, and antithrombotic therapy has been reported to prolong survival time among patients with small cell lung cancer. Additionally, coagulation factors have been shown to promote tumor cell growth, invasion, metastasis, and angiogenesis; moreover, coagulation abnormalities have been suggested as affecting tumor dissemination via multiple mechanisms.

Factor XIII (FXIII), including fibrinogen and fibrin, contribute to the final step in the coagulation cascade. FXIII, also known as fibrin stabilizing factor, is a member of the transglutaminase family, and is purported to exert anti-apoptotic effects on endothelial cells and promote angiogenic activity. Active FXIII catalyzes the formation of covalent cross links between \( \gamma \)-glutamyl and \( \varepsilon \)-lysyl residues of adjacent fibrin monomers, mechanically strengthening fibrin and protecting the newly formed fibrin network from destruction by the powerful fibrinolytic process. Since several FXIII substrates such as fibronectin and fibrinogen are known to be important in tumor stroma formation and metastasis, it has been suggested that FXIII activity may also be important in tumor development and metastasis. Accordingly, many clinical studies have reported the association of FXIII with human malignancies, including oral cancer, hepatocellular carcinoma, ovarian cancer, and leukemia. However, the role of FXIII in NSCLC has not yet been studied.

The purpose of this study was to compare FXIII activity in NSCLC patients with that in matched healthy subjects, and to determine whether there are differences in FXIII activity level according to histological type and TNM stage.

MATERIALS AND METHODS

Subjects

The NSCLC patients were prospectively enrolled at Korea University Ansan Hospital from September 2009 to March 2010. NSCLC was diagnosed through biopsies of primary lesions in patients with abnormalities on plain chest radiography and chest computed tomography scans. The stages of lung cancer were determined according to the National Comprehensive Cancer Network guidelines. Participants with histories of cancer in other organs, coagulopathy, diabetes mellitus, dyslipidemia, cardiovascular disease, or any medications were excluded. The study protocol was approved by the institutional review board of the Korea University Ansan Hospital and informed consent was obtained from all study participants.

Factor XIII activity assay

Plasma samples were collected from NSCLC patients and healthy subjects, and stored at -80°C. The FXIII activity assay was performed using fluorescence-based protein arrays. To fabricate the fibrinogen arrays, well-type amine arrays were incubated with fibrinogen. Reaction mixtures were prepared in a solution containing \( \text{CaCl}_2 \), thrombin and plasma. An aliquot of the reaction mixture was then applied to each of the array wells. After washing, FXIII-catalyzed cross-linking of biotinamido pentylamine and fibrin were probed with Cy3-conjugated streptavidin. The arrays were dried and scanned with a fluorescence scanner using a 543 nm laser (ScanArray Express, PerkinElmer Life and Analytical Sciences, Boston, MA, USA). The fluorescence intensity of array spots measured with the ScanArray Express program was representative of the FXIII activity in each sample. The FXIII activity was expressed as Loewy unit per milliliter (Loewy U/mL).

Statistical analysis

Differences in baseline characteristics between NSCLC patients and healthy subjects were analyzed using the Mann-Whitney test and presented as median and interquartile ranges (IQR). In subgroup analysis, the associations be-
RESULTS

Subject characteristics

Table 1 presents the baseline characteristics of the participants. The mean age of the 28 NSCLC patients was 64.4 years; 22 (78.6%) were male. There were no significant differences in age, gender, height, weight, BMI, smoking status and smoking amount between the NSCLC and healthy group. The histological types and stages of the NSCLC group are as follows: 13 adenocarcinomas, 11 squamous cell carcinomas, and four undifferentiated carcinomas; four stage I, two stage II, 12 stage III, and 10 stage IV NSCLCs (Table 2). The median activated prothromboplastin time (aPTT) was 29.0 second (normal range: 30-47 seconds).

Factor XIII activity

The median FXIII activity level of the NSCLC group (24.2 Loewy U/mL, IQR 14.9-40.4 Loewy U/mL) was significantly higher than that of the healthy group (17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) \((p=0.01)\) (Table 1). FXIII activity in patients with squamous cell carcinoma (median 28.7 Loewy U/mL, IQR 20.3-42.2 Loewy U/mL) was significantly higher than in the healthy group (median 17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL, \(p=0.01\)) (Fig. 1). However, there were no differences in FXIII activity between the healthy group and patients with adenocarcinoma (median 28.7 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) \((p=0.38)\) and between the patients with adenocarcinoma and squamous cell carcinoma \((p=0.12)\). In addition, there were no differences in FXIII activity between patients with adenocarcinoma and those with squamous cell carci-

---

Table 1. Basic Characteristics of Participants

|                  | NSCLC group | Healthy group | \(p\) value |
|------------------|-------------|---------------|-------------|
| Participants (number) | 28          | 28            | -           |
| Gender, male : female (number) | 22 : 6      | 22 : 6        | -           |
| Age (yrs)        | 64.4±9.2    | 65.4±10.1     | 0.55        |
| Height (cm)      | 162.0±8.7   | 161.1±8.9     | 0.72        |
| Weight (kg)      | 60.5±8.7    | 62.9±10.0     | 0.17        |
| BMI (kg/m²)      | 23.1±2.9    | 24.1±2.6      | 0.15        |
| Smoking status (number) |           |               |             |
| Current smoker   | 12          | 12            | -           |
| Ex-smoker        | 7           | 7             | -           |
| Non-smoker       | 9           | 9             | -           |
| Smoking amount (pack×yrs) | 29.4±26.4  | 27.2±27.6     | 0.72        |
| FXIII activity (Loewy U/mL) (median, IQR) | 24.2, 14.9-40.4 | 17.5, 12.6-26.4 | 0.01       |

BMI, body mass index; NSCLC, non-small cell lung cancer; FXIII activity, factor XIII activity; IQR, interquartile range.

Table 2. Characteristics of NSCLC Patients

|                  | NSCLC group (n=28) |
|------------------|--------------------|
| Histological type of lung cancer, n (%) |                |
| Adenocarcinoma   | 13 (46.4)          |
| Squamous cell carcinoma | 11 (39.3) |
| Undifferentiated type | 4 (14.3) |
| Stage of lung cancer |          |
| I                | 4 (14.3)           |
| II               | 2 (7.1)            |
| III              | 12 (42.9)          |
| IV               | 10 (35.7)          |
| CRP (mg/dL), median (range) | 0.9 (0-15.0) (Ref.*: 0-0.5) |
| aPTT (sec), median (range) | 29.0 (10.0-55.0) (Ref.*: 30-47) |
| PT (%), median (range) | 95.7 (25-159) (Ref.*: 70.0-120.0) |
| Platelet (×10⁹/L), median (range) | 239 (201-303) (Ref.*: 140-440) |
| CEA (ng/mL), median (range) | 2.8 (1.0-34.0) (Ref.*: 0-5.0) |

CRP, C-reactive protein; aPTT, activated partial thromboplastin time; PT, prothrombin time; CEA, carcinoembryogenic antigen; NSCLC, non-small cell lung cancer.

*Ref. means reference range.
FXIII activity was negatively correlated with aPTT in NSCLC patients (Fig. 3), but not with prothrombin time (PT). There was moderate negative correlation between FXIII activity and aPTT, in which the correlation coefficient was -0.38 ($p=0.04$) in itself, and -0.48 ($p=0.03$) when adjusted with PT.

DISCUSSION

The results of this study showed that FXIII activity was higher in patients with NSCLC than in the healthy group. Patients with squamous cell carcinoma and stage III and IV disease showed significantly higher FXIII activities than those of the healthy group. Additionally, FXIII activity was higher in patients with stage III disease than in patients with stages I or II. Moreover, FXIII activity was negatively correlated with aPTT in NSCLC patients (Fig. 3), but not with prothrombin time (PT). There was moderate negative correlation between FXIII activity and aPTT, in which the correlation coefficient was -0.38 ($p=0.04$) in itself, and -0.48 ($p=0.03$) when adjusted with PT.
FXIII has been shown to support metastasis primarily by limiting NK cell-mediated clearance of micrometastatic tumor cells through cross-linking fibrin, which is also supposed to function as a promoter for stable adhesion for early tumor cells through cross-linking fibrin, and participates in hemostasis, angiogenesis, wound healing and maintenance of pregnancy. The levels of FXIII-A subunit, which are converted from FXIII, are usually higher in females, elderly patients, and smokers. Therefore, in our study, 28 NSCLC patients were compared to those of strictly matched healthy subjects and smokers.

Studies of FXIII activity in tumor biology are scarce. FXIII has been shown to support metastasis primarily by limiting NK cell-mediated clearance of micrometastatic tumor cells through cross-linking fibrin, which is also supposed to function as a promoter for stable adhesion for early tumor metastasis. FXIII also plays an important role in tumor angiogenesis by direct stimulation of endothelial cell proliferation, migration and survival. In this study of NSCLC, FXIII activity in patients with advanced stage disease was significantly higher than that in patients with earlier stage disease, which was consistent with a previous study regarding the potential role of FXIII in tumor biology. The reasons for the increased FXIII activities are supposed to be due to increased FXIII-A secretion from damaged tumor-associated macrophages and increased vascular permeability factor/vascular endothelial growth factor (VEGF), which is a key element for angiogenesis and coagulation/fibrinolysis activation. This phenomenon was predominant in squamous cell carcinoma rather than in adenocarcinoma, according to a previous report. Considering our results, FXIII activity may be a potential novel biomarker for NSCLC, and further investigations are necessary to reveal the effect of FXIII activity on cell type, progression, and prognosis in NSCLC patients. However, there are some contradictions with the reports in patients with breast cancer and advanced gastrointestinal tumors, as these patients had reduced FXIII levels.

There are some limitations to the present study. First, the sample size was small. In order to match age, gender, BMI, smoking status, and smoking amount and exclude factors which could potentially influence FXIII activity, a limited number of NSCLC patients and participants from KHGS were enrolled. Therefore, it was impossible to perform subgroup analysis of undifferentiated cell types or make comparisons with other cell types. Second, because this was a cross-sectional study, the effect of FXIII activity on prognosis could not be evaluated. Finally, the relationship of other coagulation factors such as fibrinogen and D-dimer were not analyzed.

In conclusion, FXIII activity in NSCLC patients and patients with advanced stages was significantly increased compared to those of strictly matched healthy subjects and patients with earlier stages of disease, respectively. These findings suggest potential roles for FXIII in NSCLC progression. Therefore, further studies with larger sample sizes are necessary to investigate the role of FXIII in lung cancer biology.

REFERENCES

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(1 Suppl):191-202.
3. Pastorino U. Lung cancer screening. Br J Cancer 2010;102:1681-6.
4. Coote LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
5. Montuenga LM, Pio R. Current challenges in lung cancer early detection biomarkers. Eur J Cancer 2009;45 Suppl 1:377-8.
Factor XIII Activity on Non-Small Cell Lung Cancer

6. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005;3:25.

7. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Lov V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-8.

8. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30:201-7.

9. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401.

10. Palumbo JS, Kombirinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-9.

11. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006;4:19-25.

12. Katona E, Nagy B, Kappelmayer J, Baktai G, Kovács L, Mári aligeti T, et al. Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation. J Thromb Haemost 2005;3:1407-13.

13. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002;12:187-95.

14. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.

15. Jones JM, Mcgonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006;53:97-101.

16. Vairaktaris E, Vassiliou S, Yapijakis C, Spyridonidou S, Vylliotis A, Derka S, et al. Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII. Oncol Rep 2007;18:1537-43.

17. An Y, Bekesova S, Edwards N, Goldman R. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma. Dis Markers 2010;29:11-20.

18. Kiss F, Heveszy Z, Veszprémi A, Katona E, Kiss C, Vereb G, et al. Leukemic lymphoblasts, a novel expression site of coagulation factor XII subunit A. Thromb Haemost 2006;96:176-82.

19. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;:15-9.

20. Kim SJ, Suk MH, Choi HM, Kimm KC, Jung KH, Lee SY, et al. The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea. Int J Tuberc Lung Dis 2006;10:1393-8.

21. Kwon MH, Kong DH, Jung SH, Suh IB, Kim YM, Ha KS. Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma. Anal Chem 2011;83:2317-23.

22. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008;6:812-9.

23. Bobek V, Kovarík J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-9.

24. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001;17:667-73.

25. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999;25:167-72.

26. Adány R, Bárdos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci 2003;60:1049-60.

27. Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 2005;3:1337-48.

28. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001;86:57-65.

29. Bárdos H, Juhász A, Répássy G, Adány R. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 1998;80:767-82.

30. Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003;89:177-84.

31. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006;53:97-101.

32. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999;25:167-72.

33. Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 2005;3:1337-48.

34. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001;86:57-65.